Instruction for use: Prevenar

Dosage form: Suspension for intramuscular injection

Active substance: Vaccinum antipneumococcum

ATX

J07AL02 Pneumococcal purified polysaccharide antigen conjugated

Pharmacological group:

Vaccines, serums, phages and toxoids

The nosological classification (ICD-10)

A16 Tuberculosis of respiratory organs, not confirmed bacteriologically or histologically

A40.3 Septicemia caused by Streptococcus pneumonia

B24 Disease caused by human immunodeficiency virus [HIV], unspecified

B95.3 Streptococcus pneumonia

C80 Malignant neoplasm without specification of localization: Malignant tumor; Malignant neoplasm; Malignant neoplasms of different localization; Malignant tumors; Eton-Lambert syndrome; Locally prevalent forms of malignant neoplasms; Metastatic ascites; Metastatic ascites; Cerebellar degeneration in tumors; Hereditary cancers; Metastatic tumors; Cancer ascites; Solid tumors

D73.0 Hypersplenism

D84.9 Unspecified Immunodeficiency: Pneumonia in immunodeficient states; Autoimmune disease; Autoimmune diseases; Severe immunodeficiency; immune deficiency; Immunodeficiency; immunodeficiency diseases; Immunodeficiency states due to surgery; Immunotherapy for cancer; Immunomodulation; Infections in patients with weakened immune systems; Correction of immune deficiency; Correction of immunodeficiencies; Correction of a weakened immune system; Correction of a weakened immunity in immunodeficient states; Violation of immunity; Violation of the immune status; Immune System Disorders; Primary immunodeficiency; Maintaining immunity; Lowering the body's defenses; Lowering the immunity; Lowering the immunity of colds and infectious diseases; The decrease of the immune status; Lowered resistance to infections; Lowered resistance to infections and colds; Lowered resistance; Immunosuppression; Predisposition to colds; acquired immune deficiencies; Radiation immunodeficiency; The development of immunodeficiency; Immune dysfunction syndrome; immunodeficiency syndrome; primary immunodeficiency syndrome; Reducing the body's defenses; Immunosuppression; Reduced immune defense; Reducing local immunity; Reducing the total body resistance; The decrease in cell-mediated immunity; Reduced resistance to infections in children; Reducing the body's resistance; Reduced resistance; reduced immunity; Status immunodeficiency; Stimulation of the processes of nonspecific immunity; Heavy selective secondary immunodeficiency; immunity Oppression; Primary immunodeficiency

E14 Diabetes mellitus, unspecified: Severe vascular complication of diabetes: Diabetes; Diabetic asthenia; Thyroid dysfunction; Diabetes; Obesity in the background of diabetes

G00.1 Pneumococcal meningitis: Recurrences of pneumococcal meningitis

G96.0 Spread of cerebrospinal fluid [CSF]

H66.9 Otitis media, unspecified: Chronic otitis media; Otitis; Average otitis media; Middle ear infection; Otitis media in children

I99 Other and unspecified disorders of the circulatory system: angiopathy; Arterial angiopathy; Atherosclerotic angiopathy; Hemodynamic right heart defects; Hemodynamic defect of the right heart; coronary angiopathy; Infringement of blood circulation; Violation of circulation; Violation microcirculation in organs and tissues; Peripheral circulatory disorders; Disorders of the peripheral circulation in the extremities; circulatory failure; Hemodynamic instability occlusion of arteriovenous origin; Acute circulatory failure; Psevdostenokardicheskie state; Psevdostenokardicheskoe disorder; circulatory disorder; Cardiovascular diseases; Vascular insufficiency; Thrombosis arteriovenous shunt; Thrombosis with prosthetic heart valves; Deterioration of blood circulation in the pelvic organs; Functional failure of the cardiovascular system; Functional disorders of the cardiovascular system; Chronic arterial insufficiency; Chronic heart failure; Age-related vascular disease; The risk of thrombosis

J13 Pneumonia caused by Streptococcus pneumonia: Pneumonia streptococcal; Pneumococcal pneumonia; Infections of pneumococcal etiology, especially respiratory tract; Pneumococcal infections

J18 Pneumonia without specification of pathogens: Alveolar pneumonia; Community-acquired pneumonia atypical; Community-acquired pneumonia non-pneumococcal; Pneumonia; Inflammation of the lower respiratory tract; Inflammatory lung disease; Shared pneumonia; Respiratory and lung infections; Infections of the lower respiratory tract; Cough with inflammatory diseases of the lungs and bronchi; Croupous pneumonia; Nosocomial pneumonia; Exacerbation of chronic pneumonia; Acute community-acquired pneumonia; Acute pneumonia; Focal pneumonia; Pneumonia abscessing; Pneumonia bacterial; Pneumonia croupy; Pneumonia of focal; Pneumonia with difficulty in sputum discharge; Pneumonia in AIDS patients; Pneumonia in children; Septic pneumonia; Chronic Obstructive Pneumonia; Chronic pneumonia; Lymphoid interstitial pneumonia

J45 Asthma: Asthma of physical effort; Asthmatic conditions; Bronchial asthma; Bronchial asthma of light course; Bronchial asthma with difficulty in sputum discharge; Bronchial asthma of severe course; Bronchial asthma physical effort; Hypersecretory asthma; The hormone-dependent form of bronchial asthma; Curbing asthma attacks with bronchial asthma; Non-allergic bronchial asthma; Night Asthma; Exacerbation of bronchial asthma; Attack of bronchial asthma; Endogenous forms of asthma; Night attacks of asthma; Cough with bronchial asthma

J98.9 Respiratory disorder, unspecified: Hypoventilation; Hypoventilation of the lungs; Hypoxemia; Medicinal damage of the lungs; Disturbances from the respiratory center; Functional disorders of the respiratory system; Arterial hypoxemia; Toxic changes in the lung at elevated oxygen pressure

K76.9 Liver disease, unspecified: Change in liver function in heart failure; Restoration of impaired liver function; Severe liver function disorders; Hepatitis; Hepatosis; Hepatopathy; Liver dysfunction; Diseases of the liver; Impaired liver function; Dysfunction of the liver; Infringements of function of a liver of an inflammatory etiology; Functional liver failure; Functional disorders of the liver; Chronic liver disease; Chronic diffuse liver disease; Enterogenic diseases of the gallbladder and liver

N28.9 Kidney and ureter's disease, unspecified: Disturbance of ureter function; Autoimmune kidney damage; Kidney Diseases; Infringement of a renal blood flow; Impaired renal function; Impaired renal function; Nondiabetic nephropathy; Insufficiency of excretory function of the kidneys; Nephrogenic osteopathy; Nephropathic syndrome; Nephropathy of minimal changes; Maintaining kidney function; Chronic kidney disease; Megaloureter

P07.3 Other cases of prematurity: Preterm infants; Preterm neonatal; Dysbiotic disorder of the intestine in premature infants; Exercising preterm infants; Premature baby

R54 Age-related disease: External signs of aging; Age-related eye disease; Age-related visual impairment; Age-related vascular disease; Age constipation; Age-related changes in visual acuity; Age-related changes in the brain involutional; Age-related disorders; Age-related hearing loss; gerontological practice; senile dementia; Deficiency of calcium and vitamin D3 in the elderly; cerebral vascular disease and age-related; involutionary depression; involutional depression; Correction of metabolism in middle and old age; Malnutrition in elderly and senile age.; senile dementia; senile dementia; senile depression; senile colpites; senile psychosis; Syndrome of age involution; Hearing loss age; Aging; Brain Aging; The aging of the organism; senile dementia; senium; Senile involutional psychosis; senile psychosis; Memory impairment in elderly patients; Conduct disorders in the elderly

R78.8.0 * Bacteremia: Persistent bacteraemia; Bacteremia

Y43.4 Adverse reactions in the therapeutic use of immunosuppressive agents: Treatment with immunosuppressants

Z23.8 The need for immunization against another single bacterial disease

Z29.1 Prophylactic immunotherapy: Vaccination against viral infections; donor Vaccination; Vaccination and revaccination; Vaccination of newborns; Vaccination against hepatitis B; Immunization; Correction of the immune status; Therapeutic and prophylactic immunization; Preventive immunization; Specific immunoprophylaxis; Stimulation of the processes of nonspecific immunit

Z54 recovery period: The recovery period; The recovery period after illness; Recovery; The recovery from the flu and colds; Recovery after illness; The lack of mineral salts in the period of convalescence; The period of recovery after illness; The period of recovery after illness and surgery; The period of recovery after a serious illness; The period of convalescence after illness; rehabilitation period; rekovalestsentsii period after infectious diseases; decubation; The period of convalescence after surgery and infectious diseases; The period of convalescence after prolonged infections; The period of convalescence after serious diseases; The period of convalescence after severe infections; Rehabilitation period; convalescent state; Convalescence after illness; Convalescence after infectious diseases; Convalescence after debilitating diseases; Convalescence after infectious diseases; Convalescence at an elevated blood loss; Status of convalescence after illness

Z72.0 Tobacco use: tobacco smoking, Smoking

Z96.2 Presence of otological and audiological implants

Composition and release form

Suspension for intramuscular administration 1 dose (0.5 ml)

Pneumococcal conjugates (polysaccharide + CRM197):

Polysaccharide serotype 4 2 μg

Polysaccharide serotype 6B 4 μg

Polysaccharide serotype 9V 2 μg

Polysaccharide serotype 14 2 μg

Oligosaccharide serotype 18C 2 μg

Polysaccharide serotype 19F 2 μg

Polysaccharide serotype 23F 2 μg

Carrier protein CRM 197 »20 μg

Auxiliary substances: aluminum phosphate; sodium chloride; water for injections

In disposable syringes of 0.5 ml, with a capacity of 1 ml (complete with a stainless steel needle in an individual case); In the plastic package 1 or 5 sets, in a pack of cardboard 1 (1 set) or 2 (5 sets each) packaging.

Pharmachologic effect

Mode of action - Immunomodulating.

Dosing and Administration

Only IM, anterolateral hip surface (children under 2 years) or in the deltoid muscle of the shoulder (children over 2 years old). Do not administer Prevenar intravenously!

Before applying the Prevenar vaccine, shake the contents of the syringe until a homogeneous suspension is obtained. Do not use if foreign particles are detected when inspecting the contents of the syringe or the contents are not a homogeneous suspension of white color. A white cloudy sediment is allowed.

Scheme of vaccination of children

At the age of 2 to 6 months - three doses of a 0.5 ml vaccine each, with an interval between doses of at least 1 month, the first dose is usually administered at the age of 2 months. The fourth dose (ie, revaccination) is recommended to be administered in the second year of life, optimally - at 12-15 months.

For children to whom vaccination was not initiated in the first half of the year, the appointment of Prevenar is carried out according to the following schemes:

At the age of 7 to 11 months - 2 doses of 0.5 ml each, with an interval of at least 1 month between injections. The third dose (i.e. revaccination) is recommended in the second year of life.

At the age of 12 to 23 months - 2 doses of 0.5 ml each, with an interval between injections of at least 2 months.

At the age of 2 to 5 years - 1 dose of 0.5 ml once.

The need for an additional dose after each of the above immunization regimens has not been established.

Conditions of supply of pharmacies

On prescription.

Storage conditions of the drug Prevenar

At a temperature of 2-8 ° C (do not freeze).

Keep out of the reach of children.

Shelf life of the drug Prevenar

3 years.

Do not use after the expiry date printed on the package.